XIAP-mediated protection of H460 lung cancer cells against cisplatin

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 75-84

  Cheng, Yow Jyun ^a   Jiang, Hang Shiang ^a   Hsu, Shih Lan ^b   Lin, Li Chiung ^a   Wu, Chieh Liang ^a,b   Ghanta, Vithal K ^c   Hsueh, Chi Mei ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Caspase 3; Cisplatin; Drug resistance; NSCLC; XIAP

Indexed keywords

CASPASE 3; CISPLATIN; EMBELIN; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; REGULATORY MECHANISM;

APOPTOSIS; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; RNA, SMALL INTERFERING; TIME FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 73449109091     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.003     Document Type: Article

References (33)

1. Akaboshi M., Kawai K., Maki H., Akuta K., Ujeno Y., and Miyahara T. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn. J. Cancer Res. 83 (1992) 522-526
2. Alberti W., Anderson G., Bartolucci A., and Bell D. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899-909
3. Aneja R., Zhou J., Zhou B., Chandra R., and Joshi H.C. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol. Cancer Ther. 5 (2006) 2366-2377
4. Arany L., and Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 23 (2003) 460-464
5. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
6. Cilenti L., Kyriazis G.A., Soundarapandian M.M., Stratico V., Yerkes A., Park K.M., Sheridan A.M., Alnemri E.S., Bonventre J.V., and Zervos A.S. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am. J. Physiol. Renal Physiol. 288 (2005) F371-F379
7. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
8. Eguchi Y., Shimizu S., and Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. 57 (1997) 1835-1840
9. Ferreira C.G., Tolis C., Span S.W., Peters G.J., van Lopik T., Kummer A.J., Pinedo H.M., and Giaccone G. Drug-induced apoptosis in lung cancer cells in not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin. Cancer Res. 6 (2000) 203-212
10. Fry W.A., Menck H.R., and Winchester D.P. The national cancer data base report on lung cancer. Cancer 77 (1996) 1947-1955
11. Gonzalez V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 59 (2001) 657-663
12. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13 (1999) 1899-1911
13. Hu Y., Cherton-Horvat G., Dragowska V., Baird S., Korneluk R.G., Durkin J.P., Mayer L.D., and LaCasse E.C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9 (2003) 2826-2836
14. Ihde D.C., and Minna J.D. Non-small cell lung cancer Part II: treatment. Curr. Probl. Cancer 15 (1991) 105-154
15. Jassem J. Chemotherapy of advanced non-small cell lung cancer. Ann. Oncol. 10 (1999) S77-S82
16. Jones N.A., Turner J., McIlwrath A.J., Brown R., and Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol. Pharmacol. 53 (1998) 819-826
17. Kroemer G., Zamzami N., and Susin S.A. Mitochondrial control of apoptosis. Immunol. Today 18 (1997) 44-51
18. Mareninova O.A., Sung K.F., Hong P., Lugea A., Pandol S.J., Gukovsky I., and Gukovskaya A.S. Cell death in pancreatitis: caspases protect from necrotizing pancreatitis. J. Biol. Chem. 281 (2006) 3370-3381
19. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., Stremmel W., Krammer P.H., and Galle P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99 (1997) 403-413
20. Nikolovska-Coleska Z., Xu L., Hu Z., Tomita Y., Li P., Roller P.P., Wang R., Fang X., Guo R., Zhang M., Lippman M.E., Yang D., and Wang S. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47 (2004) 2430-2440
21. Notarbartolo M., Cervello M., Paola P., Dusonchet L., Meli M., and D'Alessandro N. Expression of the IAPs in multidrug resistant tumor cells. Oncol. Rep. 11 (2004) 133-136
22. Park M.S., De Leon M., and Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 13 (2002) 858-865
23. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34 (1998) 1535-1544
24. Raffo A.J., Kim A.L., and Fine R.L. Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 19 (2000) 6216-6228
25. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature 87 (1997) 773-776
26. Rosenberg B. Platinum complexes for the treatment of cancer: why the search goes on. In: Lipper B. (Ed). Cisplatin: chemistry and Biochemistry of a leading anticancer drug (1999), WILEY-VCH Inc., Weinheim (Germany) 3-27
27. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3 (2002) 401-410
28. Sanchez-Alcazar J.A., Khodjakov A., and Schneider E. Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res. 61 (2001) 1038-1044
29. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.-J., Pedersen I.M., Kitada S., Scott F.L., and Bailly-Maitre B. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
30. Sibani S., Price G.B., and Zannis-Hadjopoulos M. Decreased origin usage and initiation of DNA replication in haploinsufficient HCT116 Ku80+/- cells. J. Cell Sci. 118 (2005) 3247-3261
31. Srinivasula S.M., Gupta S., Datta P., Zhang Z., Hegde R., Cheong N., Fernandes-Slnemri T., and Alnemri E.S. Inhibitor of apoptosis proteins are substracts for the mitochondrial serine protease Omi/HtrA2. J. Biol. Chem. 278 (2003) 31469-31472
32. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., Lee R.A., Robbins P.D., Fernandes-Slnemri T., Shi Y., and Alnemri E.S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410 (2001) 112-116
33. Tymianski M., Charlton M.P., Carlen P.L., and Tator C.H. Secondary Ca2+ overload indicates early neuronal injury which precedes staining with viability indicators. Brain Res. 607 (1993) 319-323